» Articles » PMID: 35486218

Cannabis for Rheumatic Disease Pain: a Review of Current Literature

Overview
Publisher Current Science
Specialty Rheumatology
Date 2022 Apr 29
PMID 35486218
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose Of Review: Changing attitudes about marijuana have led to an increase in use of medicinal marijuana, especially for painful chronic conditions. Patients ask rheumatologists for guidance on this topic. This review provides up-to-date information on the safety and efficacy of medicinal cannabis for rheumatic disease pain.

Recent Findings: The number of publications related to rheumatic disease and cannabis has increased, but recent literature skews heavily toward reviews vs primary research. Data supporting a role for cannabinoids in rheumatic disease continue to grow. Observational and survey studies show increased use of medicinal cannabis, both by people with rheumatic disease and the general population, and suggest that patients find these treatments beneficial. Prospective studies, however, including randomized controlled clinical trials, are rare and sorely needed. As medicinal cannabis use for rheumatic diseases rises, despite lack of evidence, we review the sparse data available and provide tips for conversations about medicinal cannabis for rheumatologists.

Citing Articles

The Elusive Truth of Cannabinoids for Rheumatic Pain.

Clarke H, Miles S, Peer M, Fitzcharles M Curr Rheumatol Rep. 2024; 26(11):392-402.

PMID: 39120750 DOI: 10.1007/s11926-024-01162-9.


Evidence for the use of cannabis-based medicines in osteoarthritis: a scoping review.

Xiao A, Turk T, Deol K, Zhang S, Aref H, Campbell A Clin Rheumatol. 2024; 43(8):2375-2390.

PMID: 38853226 DOI: 10.1007/s10067-024-07001-7.


Inflammatory rheumatic diseases and the risk of drug use disorders: a register-based cohort study in Sweden.

Kiadaliri A, DellIsola A, Englund M Clin Rheumatol. 2023; 43(1):81-85.

PMID: 37639149 PMC: 10774176. DOI: 10.1007/s10067-023-06755-w.


Supporting Machine Learning Model in the Treatment of Chronic Pain.

Visibelli A, Peruzzi L, Poli P, Scocca A, Carnevale S, Spiga O Biomedicines. 2023; 11(7).

PMID: 37509416 PMC: 10376077. DOI: 10.3390/biomedicines11071776.

References
1.
Azcarate P, Zhang A, Keyhani S, Steigerwald S, Ishida J, Cohen B . Medical Reasons for Marijuana Use, Forms of Use, and Patient Perception of Physician Attitudes Among the US Population. J Gen Intern Med. 2020; 35(7):1979-1986. PMC: 7352011. DOI: 10.1007/s11606-020-05800-7. View

2.
Dai H, Richter K . A National Survey of Marijuana Use Among US Adults With Medical Conditions, 2016-2017. JAMA Netw Open. 2019; 2(9):e1911936. PMC: 6755533. DOI: 10.1001/jamanetworkopen.2019.11936. View

3.
Fitzcharles M, Rampakakis E, Sampalis J, Shir Y, Cohen M, Starr M . Medical Cannabis Use by Rheumatology Patients Following Recreational Legalization: A Prospective Observational Study of 1000 Patients in Canada. ACR Open Rheumatol. 2020; 2(5):286-293. PMC: 7231516. DOI: 10.1002/acr2.11138. View

4.
Fitzcharles M, Hauser W . Cannabinoids in the Management of Musculoskeletal or Rheumatic Diseases. Curr Rheumatol Rep. 2016; 18(12):76. DOI: 10.1007/s11926-016-0625-5. View

5.
Sarzi-Puttini P, Ablin J, Trabelsi A, Fitzcharles M, Marotto D, Hauser W . Cannabinoids in the treatment of rheumatic diseases: Pros and cons. Autoimmun Rev. 2019; 18(12):102409. DOI: 10.1016/j.autrev.2019.102409. View